Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 130 participants.
Also called NCT07273838
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 130 participants
- Registry
-
NCT07273838
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07273838. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-05 (actual); primary completion 2028-08-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
- Condition
- Heart Failure
- Condition
- Acute Kidney Injury
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Yale University
- Collaborator
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Record details
- Record id
cardio:ct-nct07273838- Content hash
8cc2deed0ece0c801e1af42c2989c0cb4b22fe0bba7d507ae9bd10bd40218a58